FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to using an immunotherapeutic agent containing cell wall fragments of the virulent strain Mycobacterium tuberculosis for preparing a therapeutic agent used for the primary prevention of tuberculosis in individuals suffered the exposure of an infectious agent with a negative tuberculin skin test (TSK) response detected.
EFFECT: immunotherapeutic agent is able to stimulate the protective response, which is more effective than that elicited by common BCG vaccine, and reduces viable bacteria count in lungs and spleen of the individuals recently infected M tuberculosis.
14 cl, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREVENTIVE ANTI-TUBERCULOSIS VACCINE | 2007 |
|
RU2526910C2 |
| LIPOSOME FORMULATION SUITABLE FOR TREATING OR PREVENTING TUBERCULOSIS | 2012 |
|
RU2648842C2 |
| IMMUNOTERAPEUTIC AGENT SUITABLE FOR COMBINED TUBERCULOSIS TREATMENT COUPLED WITH OTHER MEDICAL PRODUCTS | 2004 |
|
RU2341287C2 |
| MTB-C VACCINE AGAINST ASTHMA | 2012 |
|
RU2602771C2 |
| COMPOSITIONS FOR USE AS A PREVENTIVE AGENT FOR PATIENTS WITH A RISK OF TB INFECTION OR AS A SECONDARY AGENT FOR THE TREATMENT OF PATIENTS WITH TB INFECTION | 2019 |
|
RU2778094C2 |
| VACCINES OF RECOMBINANT INTRACELLULAR PATHOGENS AND USES THEREOF | 2001 |
|
RU2266132C2 |
| ANTITUBERCULOUS VACCINE | 2007 |
|
RU2443773C2 |
| IMMUNOGENIC COMPOSITION (VERSIONS) BASED ON RECOMBINANT INTRACELLULAR PATHOGEN | 2003 |
|
RU2337707C2 |
| COMPOSITIONS AND METHODS FOR TREATING ACTIVE MYCOBACTERIUM TUBERCULOSIS INFECTION | 2013 |
|
RU2659149C2 |
| HYBRIDISATION OF HETEROOLIGOMER MYCOBACTERIAL ANTIGENS | 2015 |
|
RU2695462C2 |
